There was intentionally suppressed negative and questioning sentiments about Perifosine's Phase II results. Any big pharm would have ran a Phase II-B, but then again, their investors are a lot smarter than the investors in a small cap like KERX. This stock is very appealing to the small retail investor as a vehicle for gambling in a biotech but truth be told, this is not at all what you think of when you think biotech company. We're talking about something puny and reckless here, a small fish in a big pond.
Believe it or not, there was constant discussion of the idea that Zerenex would make KERX worth $3/share just several months ago, so this is not exactly the most profitable scenario regardless sitting at about 2.50 with a high chance that these highschool scientists might have forgotten part of their study design before they went out the door.